Company / SG&A Expense
Crinetics Pharmaceuticals, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$191.3M
FY2025
5-year range
$24.5M / $191.3M
FY2021-FY2025
Trend
+91.8%
vs FY2024
Sector context
#73 of 213
Health Care
What the data says
At $191M, Crinetics Pharmaceuticals, Inc.'s sg&a expense ranks #141 of 213 in the Health Care sector. SG&A Expense has increased for 7 consecutive years, from $2M in FY2018 to $191M in FY2025.
Based on SEC 10-K filings.
$191M in FY2025 with a 5-year CAGR of +95.7%.
Increased from $58M to $191M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +65.3%
- 5-Year CAGR
- +95.7%
- 10-Year CAGR
- -
Sector benchmark
#141 of 213 in Health CareTop 66% of 213This company $191.3M Sector average $722.3M
▼
-73.5% below sector average
Key checks
Key Insights
- Crinetics Pharmaceuticals, Inc.'s sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +95.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 91.8% year-over-year.
- Ranks #73 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $191.3M | +91.8% |
| FY2024 | $99.7M | +71.7% |
| FY2023 | $58.1M | +37.0% |
| FY2022 | $42.4M | +72.9% |
| FY2021 | $24.5M | +268.3% |
| FY2020 | $6.7M | +243.4% |
| FY2019 | $1.9M | +26.5% |
| FY2018 | $1.5M | -20.9% |
| FY2017 | $1.9M | +26.5% |
| FY2016 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026